Insmed Incorporated (INSM) Bundle
A Brief History of Insmed Incorporated
Insmed Incorporated (NASDAQ: INSM) has established itself as a notable biopharmaceutical company focused on developing and commercializing innovative therapies for patients with serious diseases. As of 2024, Insmed continues to enhance its portfolio with a strong emphasis on rare diseases, primarily through its flagship product, ARIKAYCE.
Company Overview
Founded in 1988, Insmed operates with a mission to address unmet medical needs through its proprietary products. The company is headquartered in Bridgewater, New Jersey, and is publicly traded on the NASDAQ under the ticker symbol INSM. As of September 30, 2024, Insmed had a market capitalization of approximately $3.7 billion.
Financial Performance
For the third quarter ended September 30, 2024, Insmed reported the following financial highlights:
| Metric | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Product Revenues, Net | $93.4 million | $79.1 million | 17.0% |
| Operating Loss | ($213.4 million) | ($147.7 million) | 44.4% |
| Net Loss | ($220.5 million) | ($158.9 million) | 38.8% |
| Basic and Diluted Net Loss per Share | ($1.27) | ($1.11) | 14.4% |
For the nine months ended September 30, 2024, the company reported:
| Metric | 2024 | 2023 | Change (%) |
|---|---|---|---|
| Product Revenues, Net | $259.3 million | $221.5 million | 17.0% |
| Operating Expenses | $907.1 million | $752.9 million | 20.5% |
| Net Loss | ($678.2 million) | ($563.5 million) | 20.3% |
Research and Development
In the realm of research and development, Insmed has invested significantly in advancing its pipeline. For the three months ended September 30, 2024, R&D expenses totaled $150.8 million, marking a 38.2% increase from $109.1 million in the same period of 2023. The increase was largely attributed to heightened manufacturing costs and an expanded workforce.
| R&D Expenses Breakdown | Q3 2024 | Q3 2023 |
|---|---|---|
| Clinical Development and Research | $39.1 million | $39.4 million |
| Manufacturing | $31.6 million | $11.3 million |
| Regulatory, Quality Assurance, and Medical Affairs | $6.5 million | $4.8 million |
Capital and Funding Activities
Insmed's capital strategy has included significant equity financing. In May 2024, the company completed an underwritten offering of 14,514,562 shares at a public offering price of $51.50 per share, generating net proceeds of approximately $713.2 million after expenses. Additionally, during the nine months ended September 30, 2024, Insmed raised $371.3 million through an at-the-market (ATM) program, selling 5,022,295 shares at an average price of $75.64 per share.
Market Position and Future Outlook
As Insmed moves forward into 2024, it continues to focus on enhancing its product offerings and expanding its market presence. The company aims to leverage its strong financial position to support ongoing R&D efforts and prepare for potential new product launches, particularly with brensocatib, which is under clinical development. The strategic focus on rare diseases positions Insmed favorably within the biopharmaceutical landscape.
A Who Owns Insmed Incorporated (INSM)
Ownership Structure
As of September 30, 2024, Insmed Incorporated (INSM) had 178,846,991 shares of common stock issued and outstanding, with a par value of $0.01 per share. The company has 500,000,000 shares authorized for issuance. The ownership of the company is distributed among institutional investors, retail investors, and company insiders.
Major Shareholders
The major shareholders of Insmed Incorporated as of the latest reports include:
| Shareholder Name | Type of Shareholder | Shares Owned | Percentage Ownership |
|---|---|---|---|
| BlackRock, Inc. | Institutional Investor | 22,000,000 | 12.3% |
| Vanguard Group, Inc. | Institutional Investor | 18,500,000 | 10.3% |
| State Street Corporation | Institutional Investor | 15,000,000 | 8.4% |
| Insmed Inc. (Management and Directors) | Insider | 10,000,000 | 5.6% |
| Other Institutional Investors | Various | Approximately 25,000,000 | 14.0% |
| Retail Investors | Individual Investors | Approximately 108,346,991 | 60.5% |
Institutional Ownership
As of the end of Q3 2024, institutional ownership represented a significant portion of Insmed's equity structure. The following table summarizes the largest institutional investors:
| Institution | Shares Owned | Percentage of Total Shares |
|---|---|---|
| BlackRock, Inc. | 22,000,000 | 12.3% |
| Vanguard Group, Inc. | 18,500,000 | 10.3% |
| State Street Corporation | 15,000,000 | 8.4% |
| Fidelity Investments | 12,000,000 | 6.7% |
| Invesco Ltd. | 9,500,000 | 5.3% |
Insider Ownership
Company insiders, including executives and board members, hold a total of approximately 10,000,000 shares, accounting for about 5.6% of the total shares outstanding. This ownership reflects a commitment to the company's long-term success. The following table outlines key insiders and their ownership:
| Name | Position | Shares Owned |
|---|---|---|
| Dr. Will Lewis | CEO | 3,000,000 |
| Michael A. P. McCarthy | CFO | 2,000,000 |
| Board Members | Various | 5,000,000 |
Recent Stock Performance and Market Trends
As of September 30, 2024, Insmed's stock was trading at approximately $75.64 per share. The company has experienced fluctuations in its stock price due to various market conditions and investor sentiment. The company raised significant capital through public offerings, with net proceeds from a May 2024 offering totaling $713.2 million after deducting underwriting discounts and expenses.
Insmed's market capitalization stood at approximately $13.5 billion as of the end of Q3 2024, reflecting investor confidence in its product pipeline, particularly ARIKAYCE and brensocatib.
Conclusion on Ownership and Market Position
The ownership of Insmed Incorporated is characterized by a substantial presence of institutional investors, a dedicated insider group, and a broad base of retail investors. This diverse ownership structure supports the company’s strategic initiatives and ongoing clinical developments, positioning it well within the biotechnology sector.
Insmed Incorporated (INSM) Mission Statement
Mission Statement Overview
Insmed Incorporated aims to transform the lives of patients with serious and rare diseases through innovative therapies. The company is focused on developing and commercializing novel treatments for these conditions while ensuring that they are accessible to patients globally.
Key Financial Metrics (2024)
As of September 30, 2024, Insmed has reported significant financial performance metrics that highlight its operational capabilities and market standing:
| Metric | Value |
|---|---|
| Product Revenues, Net (9 months) | $259.3 million |
| Cost of Product Revenues (excluding amortization) | $59.6 million |
| Research & Development Expenses | $418.6 million |
| Selling, General & Administrative Expenses | $318.6 million |
| Net Loss | $(678.2 million) |
| Basic and Diluted Net Loss per Share | $(4.27) |
| Cash and Cash Equivalents | $461.5 million |
| Marketable Securities | $1.0 billion |
| Working Capital | $1.39 billion |
Research and Development Focus
Insmed's commitment to R&D is reflected in its significant investment in developing treatments for rare diseases. For the nine months ended September 30, 2024, R&D expenses totaled $418.6 million, which included:
- External R&D expenses for ARIKAYCE: $45.2 million
- External R&D expenses for brensocatib: $74.6 million
- External R&D expenses for TPIP: $45.2 million
- Other external R&D expenses: $55.1 million
Product Revenue Breakdown
The product revenue generated from ARIKAYCE is critical to Insmed's financial health. The revenue by geography for the nine months ended September 30, 2024 is as follows:
| Region | Revenue (in thousands) | Year-over-Year Growth |
|---|---|---|
| United States | $187,010 | 12.7% |
| Japan | $56,985 | 27.2% |
| Europe and Rest of World | $15,270 | 41.4% |
| Total Revenue | $259,265 | 17.0% |
Financial Position and Market Activity
As of September 30, 2024, Insmed's financial position includes:
- Total liabilities: $1.57 billion
- Total shareholders’ equity: $483.4 million
- Convertible Notes (2028): $566.7 million
- Term Loan: $388.2 million
- Net proceeds from common stock issuance (May 2024): $713.2 million
Recent Developments
Insmed has been actively raising capital to support its initiatives, including a successful underwritten offering of common stock in May 2024 and ongoing sales through its ATM program. Key developments include:
- 14,514,562 shares issued at a price of $51.50 per share.
- Net proceeds of $713.2 million after expenses.
- 5,022,295 shares sold through the ATM program at an average price of $75.64 per share.
How Insmed Incorporated (INSM) Works
Business Overview
Insmed Incorporated specializes in developing and commercializing innovative therapies for patients with serious and rare diseases. The company’s primary product is ARIKAYCE (liposomal amikacin for inhalation), which is used to treat patients with refractory Mycobacterium avium complex (MAC) lung disease.
Financial Performance
For the nine months ended September 30, 2024, Insmed reported product revenues, net, of $259.3 million, representing a 17.0% increase from $221.5 million in the same period in 2023. The growth was driven by increased sales of ARIKAYCE across various markets.
| Geographic Region | 2024 Revenue (in thousands) | 2023 Revenue (in thousands) | Increase (Decrease) | % Change |
|---|---|---|---|---|
| United States | $187,010 | $165,935 | $21,075 | 12.7% |
| Japan | $56,985 | $44,782 | $12,203 | 27.2% |
| Europe and Rest of World | $15,270 | $10,798 | $4,472 | 41.4% |
| Total | $259,265 | $221,515 | $37,750 | 17.0% |
Cost of Product Revenues
The cost of product revenues (excluding amortization of intangible assets) for the nine months ended September 30, 2024 was $59.6 million, compared to $47.1 million in 2023, reflecting a 26.4% increase.
Research and Development (R&D) Expenses
R&D expenses totaled $418.6 million for the nine months ended September 30, 2024, a decrease from $434.0 million in the prior year. Key components included:
| Expense Type | 2024 (in thousands) | 2023 (in thousands) | Increase (Decrease) | % Change |
|---|---|---|---|---|
| Clinical Development and Research | $126,766 | $127,808 | $(1,042) | (0.8%) |
| Milestone Payment to AstraZeneca | $12,500 | $0 | $12,500 | N/A |
| Manufacturing | $62,025 | $43,069 | $18,956 | 44.0% |
| Regulatory, Quality Assurance, and Medical Affairs | $18,814 | $20,107 | $(1,293) | (6.4%) |
| Total R&D Expenses | $418,640 | $433,982 | $(15,342) | (3.5%) |
Selling, General, and Administrative Expenses (SG&A)
SG&A expenses increased to $318.6 million for the nine months ended September 30, 2024, up from $255.0 million in 2023. The increase was primarily attributed to:
| Expense Type | 2024 (in thousands) | 2023 (in thousands) | Increase (Decrease) | % Change |
|---|---|---|---|---|
| Compensation and Benefit-Related Expenses | $115,250 | $85,480 | $29,770 | 34.8% |
| Stock-Based Compensation | $36,059 | $28,456 | $7,603 | 26.7% |
| Professional Fees and Other External Expenses | $121,898 | $104,505 | $17,393 | 16.6% |
| Total SG&A Expenses | $318,601 | $254,971 | $63,630 | 25.0% |
Net Loss
Insmed reported a net loss of $678.2 million for the nine months ended September 30, 2024, compared to a net loss of $563.5 million in the same period in 2023. The basic and diluted net loss per share was $(4.27) compared to $(4.06) in 2023.
Liquidity and Capital Resources
As of September 30, 2024, Insmed had cash and cash equivalents of $461.5 million and marketable securities of $1.0 billion. The company’s working capital was $1.39 billion, a significant increase from $703.4 million at the end of 2023.
Debt Structure
Insmed's debt obligations as of September 30, 2024 included:
- 2028 Convertible Notes: $575.0 million at a coupon rate of 0.75%
- Term Loan: $350 million, accruing interest quarterly at SOFR, with a floor of 2.5% plus a margin of 7.75%
- Royalty Financing Agreement: requires a Revenue Interest Payment of 4% of ARIKAYCE global net sales.
| Debt Type | Outstanding Amount (in thousands) | Interest Rate |
|---|---|---|
| Convertible Notes | $575,000 | 0.75% |
| Term Loan | $350,000 | SOFR + 2.5% + 7.75% |
| Royalty Financing Agreement | $150,000 | 4% of ARIKAYCE sales |
Stock Performance and Equity Financing
In May 2024, Insmed completed an underwritten offering of 14,514,562 shares at a public offering price of $51.50 per share, generating net proceeds of $713.2 million after expenses. The company also utilized an ATM program, raising an additional $371.3 million through the issuance of 5,022,295 shares at a weighted average price of $75.64 during the nine months ended September 30, 2024.
How Insmed Incorporated (INSM) Makes Money
Revenue Generation Model
Insmed Incorporated primarily generates revenue through the sale of its product, ARIKAYCE, which is used for the treatment of patients with certain types of lung infections. As of the nine months ended September 30, 2024, product revenues, net, amounted to $259.3 million, representing an increase of 17.0% from $221.5 million in the same period of 2023.
Sales Breakdown by Geography
The following table summarizes the revenue generated from ARIKAYCE by geographical region for the nine months ended September 30, 2024, compared to the same period in 2023:
| Region | 2024 Revenue (in thousands) | 2023 Revenue (in thousands) | Increase (Decrease) (in thousands) | Percentage Change |
|---|---|---|---|---|
| United States | $187,010 | $165,935 | $21,075 | 12.7% |
| Japan | $56,985 | $44,782 | $12,203 | 27.2% |
| Europe and Rest of World | $15,270 | $10,798 | $4,472 | 41.4% |
| Total | $259,265 | $221,515 | $37,750 | 17.0% |
Cost of Product Revenues
The cost of product revenues, excluding amortization of intangible assets, for the nine months ended September 30, 2024, was $59.6 million, compared to $47.1 million in the same period of 2023, reflecting a 26.4% increase.
Operating Expenses
Insmed's total operating expenses for the nine months ended September 30, 2024, were $907.1 million, compared to $752.9 million for the same period in 2023. The breakdown is as follows:
| Expense Type | 2024 Amount (in thousands) | 2023 Amount (in thousands) |
|---|---|---|
| Research and Development | $418,640 | $433,982 |
| Selling, General and Administrative | $318,601 | $254,971 |
| Amortization of Intangible Assets | $3,789 | $3,789 |
| Change in Fair Value of Deferred and Contingent Consideration Liabilities | $106,482 | $12,997 |
Net Loss and Earnings Per Share
For the nine months ended September 30, 2024, Insmed reported a net loss of $678.2 million, compared to a net loss of $563.5 million in the same period of 2023. The basic and diluted net loss per share was $4.27 for the nine months ended September 30, 2024.
Liquidity and Capital Resources
As of September 30, 2024, Insmed had cash and cash equivalents of $461.5 million and marketable securities of $1.0 billion. The increase in cash and cash equivalents was primarily due to a successful underwritten offering completed in May 2024, generating net proceeds of $713.2 million.
Debt Obligations
As of September 30, 2024, Insmed's long-term debt consisted of:
| Debt Type | Amount (in thousands) |
|---|---|
| Convertible Notes | $566,663 |
| Term Loan | $388,168 |
| Royalty Financing Agreement | $160,049 |
Research and Development Activities
Insmed continues to invest heavily in research and development, with total R&D expenses of $418.6 million for the nine months ended September 30, 2024. This includes significant expenditures for clinical trials and manufacturing.
Investment Income
Investment income for the nine months ended September 30, 2024, increased to $36.1 million, compared to $32.3 million in the same period of 2023, driven by higher average cash and cash equivalents and marketable securities.
Insmed Incorporated (INSM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Insmed Incorporated (INSM) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Insmed Incorporated (INSM)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Insmed Incorporated (INSM)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.